In a phase 1 trial, 16 patients with NHL were simultaneously infused with second-generation anti-CD19 CAR T cells containing the CD28 co-stimulatory sequences alone and with third-generation CAR T cells containing both CD28 and 4-1BB (119). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.